US FDA approves Journey Medical's drug for long-term skin condition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2024
0mins
Source: Reuters
FDA Approval: Journey Medical's drug Emrosi has been approved by the FDA for treating rosacea, leading to a nearly 12% increase in the company's shares. The drug targets inflammatory lesions and will be available commercially in early 2025.
Market Impact: Analysts predict Emrosi could capture over 50% of the current market share held by the standard treatment, Oracea, potentially generating sales of at least $150 million at peak.
Analyst Views on DERM
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 14.00 USD with a low forecast of 13.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.260
Low
13.00
Averages
14.00
High
16.00
Current: 9.260
Low
13.00
Averages
14.00
High
16.00
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
